We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MANHATTAN PHARMACEUTICALS DOSES FIRST PATIENT GROUP IN PHASE IIA TRIAL FOR OE, ITS ORAL OBESITY DRUG CANDIDATE
MANHATTAN PHARMACEUTICALS DOSES FIRST PATIENT GROUP IN PHASE IIA TRIAL FOR OE, ITS ORAL OBESITY DRUG CANDIDATE
June 29, 2006
Manhattan
Pharmaceuticals, Inc. today announced that it commenced dosing the first group
of patients in its Phase IIa clinical trial of oral Oleoyl-estrone (OE), the company's
novel drug candidate for the treatment of obesity. Patient recruitment is ongoing.
Yahoo
News (http://biz.yahoo.com/prnews/060629/nyth096.html?.v=61)
